FDA Panel Recommends Enbrel for Pediatric Patients
But experts also express concern about psoriasis drug's possible risks for children; action follows agency warning that drug label needs strengthening
Posted June 18, 2008
He added: "They're being used earlier and earlier, because they're so good. I think the FDA is being cautious. I think it's smart. What are the risks of a child being crippled and non-functioning versus the risk of cancer? Maybe, in odd cases, we need to think more and not jump in with all four limbs."
More information
The U.S. Food and Drug Administration has more on TNF blockers.
advertisement
